Please email us at [email protected] with our item No, NDC#, UPC# or the product link if you have any quetions. We are located in Oceanside, California. Search over 110,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name. Please note, Prescription items can only be ordered by a Drug Manufacturer, Wholesaler, Hospital, Governmental Medical Facility, VA, Pharmacy, Physician, Physician Assistant, Nurse Practitioner, Dentist, Podiatrist, Optometrist, Veterinarian, Naturopath, Licensed Lab, Physical Therapist & Pharmacist in their scope of practice. No order will ship, unless you you have provided us the Medical License (and DEA Lic. in case of controlled drug) and we had verified that. Rx items can only be shipped to AZ, AR, CA, CT, DE, FL, GA, GU, HI, IL, KS, KY, LA, ME, MA, MI, NJ, NY, PA, PR, TX, TN, VA, WA, WI and WV. If you are an International Physician or Pharmacist, please contact us before ordering.


Menu

Rx Item-Besponsa (INOTUZUMAB OZOGAMICIN) 0.9MG SINGLEDOSE VIAL EACH by Pfizer Ph

NDC No. 00008-0100-01 00008-100-01 0000810001   00008010001  UPC/GTIN No. 3-00080-10001-1   MPN 10001 Besponsa (INOTUZUMAB OZOGAMICIN)Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scopWant to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.comVisit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.NDC No. 00008-0100-01 00008-100-01 0000810001   00008010001  UPC/GTIN No. 3-00080-10001-1   MPN 10001 Besponsa (INOTUZUMAB OZOGAMICIN)

Rx Item-Besponsa (INOTUZUMAB OZOGAMICIN) 0.9MG SINGLEDOSE VIAL EACH by Pfizer Ph

$24526.15$23358.24

NDC No. 00008-0100-01 00008-100-01 0000810001 00008010001 UPC/GTIN No. 3-00080-10001-1 MPN 10001 Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scope of practice can order this RX Item. Rx Item No. Rx775080 Besponsa 0.9MG SINGLEDOSE VIAL EACH by Pfizer Pharma Item No. 00008-0100-01 NDC No. 00008010001 0000810001 UPC No. 300080-100011 300080

Have a question?

For: Acute Lymphoblastic Leukemia

Besponsa (inotuzumab ozogamicin) is a CD22 monoclonal antibody and calicheamicin cytotoxic agent conjugate for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). P/F, SDV, LATEX-FREE INOTUZUMAB OZOGAMICIN

BESPONSA- inotuzumab ozogamicin injection, powder, lyophilized, for solution
Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.

WARNING: HEPATOTOXICITY, INCLUDING HEPATIC VENO-OCCLUSIVE DISEASE (VOD) (ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME and INCREASED RISK OF POST-HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) NON-RELAPSE MORTALITY

HEPATOTOXICITY, INCLUDING VOD

Hepatotoxicity, including fatal and life-threatening VOD occurred in patients with relapsed or refractory acute lymphoblastic leukemia (ALL) who received BESPONSA. The risk of VOD was greater in patients who underwent HSCT after BESPONSA treatment; use of HSCT conditioning regimens containing 2 alkylating agents and last total bilirubin level ≥ upper limit of normal (ULN) before HSCT were significantly associated with an increased risk of VOD.
Other risk factors for VOD in patients treated with BESPONSA included ongoing or prior liver disease, prior HSCT, increased age, later salvage lines, and a greater number of BESPONSA treatment cycles.
Elevation of liver tests may require dosing interruption, dose reduction, or permanent discontinuation of BESPONSA. Permanently discontinue treatment if VOD occurs. If severe VOD occurs, treat according to standard medical practice [see Dosage and Administration (2.3) and Warnings and Precautions (5.1)].


INCREASED RISK OF POST-HSCT NON-RELAPSE MORTALITY

There was higher post-HSCT non-relapse mortality rate in patients receiving BESPONSA, resulting in a higher Day 100 post-HSCT mortality rate [see Warnings and Precautions (5.2)].
1. INDICATIONS AND USAGE

BESPONSA is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

2. DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage
Pre-medicate before each dose [see Dosage and Administration (2.2)].
For the first cycle, the recommended total dose of BESPONSA for all patients is 1.8 mg/m2 per cycle, administered as 3 divided doses on Day 1 (0.8 mg/m2), Day 8 (0.5 mg/m2), and Day 15 (0.5 mg/m2). Cycle 1 is 3 weeks in duration, but may be extended to 4 weeks if the patient achieves a complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), and/or to allow recovery from toxicity.
For subsequent cycles:
In patients who achieve a CR or CRi, the recommended total dose of BESPONSA is 1.5 mg/m2 per cycle, administered as 3 divided doses on Day 1 (0.5 mg/m2), Day 8 (0.5 mg/m2), and Day 15 (0.5 mg/m2). Subsequent cycles are 4 weeks in duration. OR
In patients who do not achieve a CR or CRi, the recommended total dose of BESPONSA is 1.8 mg/m2 per cycle given as 3 divided doses on Day 1 (0.8 mg/m2), Day 8 (0.5 mg/m2), and Day 15 (0.5 mg/m2). Subsequent cycles are 4 weeks in duration. Patients who do not achieve a CR or CRi within 3 cycles should discontinue treatment.
DOSAGE FORMS AND STRENGTHS

For Injection: 0.9 mg as a white to off-white lyophilized powder in a single-dose vial for reconstitution and further dilution.

NDC No. 00008-0100-01 00008-100-01 0000810001   00008010001  UPC/GTIN No. 3-00080-10001-1   MPN 10001
Besponsa (INOTUZUMAB OZOGAMICI
NDC No. 00008-0100-01 00008-100-01 0000810001 00008010001 UPC/GTIN No. 3-00080-10001-1 MPN 10001

Besponsa (INOTUZUMAB OZOGAMICIN)
Besponsa (INOTUZUMAB OZOGAMICI
Besponsa (INOTUZUMAB OZOGAMICIN)

Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop
Click above for Generics!
Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop

Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.com
Buy More Save More!
Want to do Research on this Med or need a large quantity? Email Details with quantity required to:[email protected]

Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.
AmericanPharmaWholesale.com
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.

NDC No. 00008-0100-01 00008-100-01 0000810001   00008010001  UPC/GTIN No. 3-00080-10001-1   MPN 10001
Besponsa (INOTUZUMAB OZOGAMICI
NDC No. 00008-0100-01 00008-100-01 0000810001 00008010001 UPC/GTIN No. 3-00080-10001-1 MPN 10001

Besponsa (INOTUZUMAB OZOGAMICIN)
Besponsa (INOTUZUMAB OZOGAMICI
Besponsa (INOTUZUMAB OZOGAMICIN)